Antibacterial agents: Patent highlights January 2005 to June 2005

Current Opinion in Investigational Drugs

Volumn 6, Issue 8, 2005, Pages 768-780

  Phillips, Oludotun A ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

lactam antibiotics; lactamase; Antibacterial agents; Macrolide; Oxazolidinone; Peptide deformylase; Quinoline; Quinolone

Indexed keywords

2,3 DIHYDRO 6 NITRO IMIDAZO[2,1 B]OXAZOLE DERIVATIVE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFDITOREN; CEFDITOREN PIVOXIL; CEFEPIME; CEFPROZIL; CEFTAZIDIME; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; DORIPENEM; GATIFLOXACIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PEPTIDE DEFORMYLASE INHIBITOR; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMYCIN; TAZOBACTAM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL INFECTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG STORAGE; DRUG STRUCTURE; DRUG SYNTHESIS; GASTROINTESTINAL SYMPTOM; HUMAN; MEGALOBLASTIC ANEMIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NEUROLOGIC DISEASE; NONHUMAN; PATENT; REVIEW; SIDEROBLASTIC ANEMIA; SKIN DISEASE; TABLET FORMULATION; THROMBOCYTOPENIA; TUBERCULOSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; ENZYME INHIBITORS; HUMANS; LACTAMS; MACROLIDES; OXAZOLES; QUINOLONES;

EID: 23344436543     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Pinner RW, Teutsch SM, Simonsen L, Klug LA, Graber JM, Clarke MJ, Berkelman RL: Trends in infectious diseases mortality in the United States. J Am Med Assoc (1996) 275(3):189-193.
2. Deaths by cause, sex and mortality stratum in WHO regions for 2001. World Health Report, Geneva, Switzerland (2002). http://www.who.int/whr/2002/en/whr02_annex_en.pdf
3. Lundstrom TS, Sobel JD: Antibiotics for Gram-positive bacterial infections: Vancomycin, quinupristin-dalfopristin, linezolid and daptomycin. Infect Dis Clin North Am (2004) 18(3):651-668.
4. Guay DRP: Oriavancin and tigecycline: Investigational antimicrobials for multidrug-resistant bacteria. Pharmcotherapy (2004) 24(1):58-68.
5. Rahim S, Pillai SK, Gold HS, Venkataraman L, Inglima K, Press RA: Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin Infect Dis (2003) 36(11):146-148.
6. Bozdogan B, Appelbaum PC: Oxazolidinone: Activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents (2004) 23(2):113-119.
7. Mangili A, Bica I, Snydman DR, Hamer DH: Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis (2005) 40(7):1058-1060.
8. Estrada B: The increase of macrolide resistance among streptococci. Infect Med (2002) 19(6):245.
9. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, Moellering RC, Ferraro MJ: Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet (2001) 358(9277):207-208.
10. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP: Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet (2001) 357(9263):1179.
11. Johnson AP, Tysall L, Stockdale MW, Woodford N, Kaufmann ME, Warner M, Livermore DM, Asboth F, Allerberger FJ: Emerging linezolid-resistant Enterococcus faecalls and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit. Eur J Clin Microbiol Infect Dis (2002) 21(10):751-754.
12. Centers for Disease Control and Prevention: Staphylococcus aureus resistant to vancomycin - United States. Morbidity and Mortality Report (2002) 51(26):565-567.
13. Centers for Disease Control and Prevention: Public Health Dispatch: Vancomycin-resistant Staphylococcus aureus - Pennsylvania. Morbidity and Mortality Report (2002) 51(40):902-903.
14. Centers for Disease Control and Prevention: Vancomycin-resistant Staphylococcus aureus - New York. Morbidity and Mortality Report (2004) 53(15):322-323.
15. Patel R: Clinical impact of vancomycin-resistant enterococci. J Antimicrob Chemother (2003) 51(Suppl 3):iii13-iii21.
16. Poyart C, Pierre C, Quesne G, Pron B, Berche P, Trieu-Cuot P: Emergence of vancomycin resistance in the genus Streptococcus: Characterization of a vanB transferable determinant in Streptococcus bovis. Antimicrob Agents Chemother (1997) 41(1):24-29.
17. NNIS System: National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 thorugh June 2003, issued August 2003. Am J Infect Control (2003) 31(8):481-498.
18. Andrade SS, Jones RN, Gales AC, Seder HS: Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centers: 5 Year report of the SENTRY Antimicrobial Surveillance Program (1997-2001). J Antimicrob Chemother (2003) 52(1):140-141.
19. Projan SJ: Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol (2003) 6(5):427-430.
20. Overbye KM, Barrett JF: Antibiotics: Where did we go wrong? Drug Disc Today (2005) 10(1):45-52.
21. Samaha-Kfoury JN, Araj GF: Recent developments in β-lactamases and extended spectrum β-lactamases. Br Med J (2003) 327(7425):1209-1213.
22. Phillips OA, Udo EE, Ali AAM, Al-Hassawi N: Synthesis and antibacterial activity of 5-substituted oxazolidinones. Bioorg Med Chem (2003) 11(1):35-41.
23. Reck F, Zhou F, Girardot M, Gunther K, Eyermann CJ, Hales NJ, Ramsay RR, Gravestock MB: Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduce activity against monoamine oxidase A. J Med Chem (2005) 48(2):499-506.
24. Shah PM: The need for new therapeutic agents: What is the pipeline? Clin Microbiol Infect (2005) 11(Suppl 3):36-42.